Boston Scientific Corporation's shares experienced a decline in premarket trading on Thursday following the announcement of its intention to acquire Penumbra Inc. for approximately $1.45 billion. This acquisition marks the company's largest deal in two decades, signaling a significant expansion of its market presence. The source notes that this strategic move could reshape the competitive landscape in the medical device industry.
Acquisition Details
The acquisition values Penumbra at $374 per share, which is about a 19% premium over its closing price on Wednesday. This strategic move will enhance Boston Scientific's cardiovascular portfolio, particularly in the rapidly growing mechanical thrombectomy and neurovascular segments.
Enterprise Value and Financing
The enterprise value of the deal is estimated at around $1.45 billion, calculated based on Penumbra's fully diluted share count of approximately 40 million shares, adjusted for net cash of about $470 million as of September 30, 2025. To finance the cash portion of the acquisition, which amounts to roughly $1.1 billion, Boston Scientific plans to utilize a mix of available cash and new debt.
Transaction Timeline
The transaction is anticipated to close in 2026, pending approval from Penumbra's stockholders and the fulfillment of customary closing conditions.
Ocular Therapeutix, Inc. saw a notable increase in its stock price today, contrasting with Boston Scientific's recent acquisition announcement. For more details, see the full report here.
